In another clinical trial [95], 16 CML-CP patients who underwent stable disease with imatinib or IFN-α therapy were injected with six weekly multiple p210-b3a2-derived peptide vaccines and adjuvants (CMLVAX100). The gene discussed is IFNA2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.